Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection

J Exp Med. 1992 Jan 1;175(1):305-8. doi: 10.1084/jem.175.1.305.

Abstract

Peptides from donor major histocompatibility complex (MHC) molecules were examined for their activation of allogeneically primed T cells. After immunization with either allogeneic spleen cells or a skin allograft, primed T cells proliferate in response to peptides derived from polymorphic regions of alpha and beta chains of class II allo-MHC molecules. The results demonstrate that presentation of donor-MHC peptides by host-derived antigen-presenting cells is a common event in vivo. Thus, self-restricted T cell recognition of processed alloantigens may play a critical role in transplantation. An in-depth understanding of this response may result in the development of additional molecular therapies to combat allograft rejection.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Graft Rejection*
  • Histocompatibility Antigens / immunology
  • Kinetics
  • Lymph Nodes / immunology
  • Lymphocyte Activation
  • Major Histocompatibility Complex*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred Strains
  • Skin Transplantation / immunology*
  • Spleen / immunology
  • T-Lymphocytes / immunology*

Substances

  • Histocompatibility Antigens